CTI BioPharma to Present at the Cowen 42nd Annual Healthcare Conference

CTI BioPharma Corp. (NASDAQ: CTIC) will present a corporate overview at the Cowen 42nd Annual Healthcare Conference on March 7, 2022, at 1:30 p.m. ET.

Rhea-AI Summary

CTI BioPharma Corp. (NASDAQ: CTIC) will present a corporate overview at the Cowen 42nd Annual Healthcare Conference on March 7, 2022, at 1:30 p.m. ET. This virtual event will be accessible via live webcast and replay on CTI's investor website. CTI focuses on developing targeted therapies for blood-related cancers, including their FDA-approved product VONJO (pacritinib), which treats myelofibrosis in patients with low platelet counts. The company is also conducting the Phase 3 PACIFICA study for VONJO.

Argus Session date unavailable

+17.21% session move Open Argus

Details

News Market Reaction – CTIC

The recorded move for CTIC in the trading session of this news was +17.21%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEATTLE, March 2, 2022 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ: CTIC) today announced that management will provide a corporate overview at the Cowen Annual Healthcare Conference at 1:30 p.m. ET. The conference will be held in a virtual meeting format.

Presentation details:
Event: Cowen 42^nd Annual Healthcare Conference
Date: Monday, March 7, 2022
Time: 1:30 p.m. ET

The presentation will be webcast live and available for replay from the Investors section of CTI BioPharma's website at www.ctibiopharma.com.

About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJO^TM (pacritinib), a JAK2 and IRAK1, that spares JAK1. VONJO is approved for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 × 10⁹/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement.

VONJO^TM is a trademark of CTI BioPharma Corp.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cti-biopharma-to-present-at-the-cowen-42nd-annual-healthcare-conference-301494288.html

SOURCE CTI BioPharma Corp.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will CTI BioPharma present at the Cowen Healthcare Conference?

CTI BioPharma will present at the Cowen 42nd Annual Healthcare Conference on March 7, 2022, at 1:30 p.m. ET.

How can I watch the CTI BioPharma presentation?

The presentation will be available via live webcast and for replay on CTI BioPharma's investor website.

What is VONJO and what condition does it treat?

VONJO (pacritinib) is an FDA-approved treatment for adults with intermediate or high-risk myelofibrosis and low platelet counts.

What is the PACIFICA study related to CTI BioPharma?

The PACIFICA study is a Phase 3 trial of VONJO in patients with myelofibrosis and severe thrombocytopenia.

What time is the CTI BioPharma presentation at the Cowen Conference?

The presentation is scheduled for 1:30 p.m. ET.